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Abstract
Obesity is one of the major risk factors for the Nonalcoholic Fatty Liver Disease (NAFLD) 
development, as the leading cause of chronic liver disease. NAFLD is intrinsically 
related to obesity disorders, especially insulin resistance and dyslipidemia. Interaction 
between NAFLD and obesity still needs further clarification, and it is necessary to der-
temine the mechanisms of these disorders in animal models of disease. Such models 
are usually the result of genetic and/or nutritional modifications, considering metabolic 
and histological changes commonly seen in humans. Obesity induced in rodents occur 
mainly through HFD, HCD, FFD or genetic alterations like in Lep, Acox, KKy mod-
els. These models are analogous to NAFLD development, since the increasing visceral 
fat is highly associated with the accumulation of fat in the form of triglycerides in the 
liver. Inflammatory markers such as TNF-alpha and IR are active in the predisposition 
of lipolysis. Hepatic inflammation during NAFLD can also be unleashed by oxidative 
stress. However, the mechanisms involved in the progression from NAFLD to NASH 
are not yet elucidated, as some models have shown unexpected outcomes such as severe 
malnutrition or obesity markers absence and IR after the use of Minimal-change dis-
ease (MCD) therapies and drugs, respectively. Thus, it is important to evaluate different 
animal models of obesity able to induce the profile of NAFLD and NASH disease in 
humans, assessing their mechanisms of action. The aim of this chapter is to have a com-
parative analysis of animal models commongly used in the pathophysiology of obesity 
that present NAFLD/NASH.
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1. Introduction
The rapid increase in the rate of obesity is a health problem critical in developed countries. 
Obesity is associated with a number of health problems that are often summarized together 
as metabolic syndrome and involve the development of insulin resistance, type 2 diabetes, 
cardiovascular disease and fatty liver disease [1].
Nonalcoholic Fatty Liver Disease (NAFLD) is the leading cause of chronic liver disease affect-
ing 20–30% of the world’s adult population, and is characterized by a buildup of fat, mainly 
in the form of triglycerides, in the hepatocyte cytoplasm, exceeding 5–10% of the cell weight, 
verified histologically or by imaging techniques. It requires exclusion of other causes of ste-
atosis, such as excessive alcohol consumption, drugs or genetic diseases [2, 3]. About 20–30% 
of individuals with NAFLD can develop Non-alcoholic steatohepatitis (NASH) [4], a more 
severe disease condition related to metabolic abnormalities associated with obesity, namely 
hyperinsulinemia, dyslipidemia, and ectopic lipid accumulation [5]. More specifically, NASH 
is associated with lobular inflammation, hepatocellular damage and/or hepatic fibrosis [4].
NAFLD is common in Western countries, usually associated with the main characteristics of 
the metabolic syndrome, such as obesity, insulin resistance and hyperlipidemia [6]. Data from 
the U.S. National Health and Nutrition Examination Surveys, collected from 1988 to 2008, 
show a 2-fold higher prevalence of NAFLD, concomitant with the increased or increasing 
prevalence of metabolic conditions such as obesity and insulin resistance [7].
In this context, obesity induction with the development of hepatic steatosis in animal models is 
discussed. Animal models of obesity focused on NAFLD and NASH, as well as pathophysiolog-
ical aspects related to obesity and liver diseases were systematically addressed in this chapter.
2. NAFLD pathophysiology aspects
The main mechanism related to the development of hepatic steatosis are: increased supply 
of free fatty acids due to increased lipolysis of visceral/subcutaneous adipose tissue and/or 
increased lipid intake; reduction of free fatty acid oxidation; increased hepatic de novo lipo-
genesis; and decreased hepatic secretion of very low density lipoprotein (VLDL). In addition, 
during NAFLD there is an imbalance between the intrahepatic production of triglycerides 
(TG) (derived mainly from plasma fatty acids delivered to the liver and not oxidized as a 
fuel) and the removal of intrahepatic TG (mainly exported from the liver to very low density 
lipoproteins, VLDL-TG) [8, 9], as shown in Figure 1.
TGs are the lipids that accumulate most in hepatocytes in NAFLD. TGs are synthesized through 
various enzymatic steps of glycerol and fatty acids condensation after activation thereof to 
their acyl-CoA esters. The liver obtains fatty acids from the circulation from the hydrolysis 
(lipolysis) of triglycerides in adipocytes in the post-absorptive state and, to a lesser degree, the 
postprandial lipolysis of triglyceride-rich particles (chylomicrons and VLDL). Fatty acids are 
released from triglyceride stores in adipose tissue through the action of the sensitive hormone 
lipase (located in adipocytes). These fatty acids upon their release into circulation are bound to 
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albumin. The peripheral tissues, in turn, receive fatty acids as substrates for oxidation (mainly 
muscle) and storage (adipose tissue), through the action of endothelial lipoprotein lipase on 
particles rich in circulating triglycerides, either VLDL secreted by the liver, or chylomicrons 
delivered to lymphatic circulation after intestinal absorption of lipids [10].
During fat digestion, medium and short chain fatty acids are absorbed directly into the por-
tal circulation. Whereas long chain fatty acids (C > 14) are mainly reesterified in chylomi-
crons, but a proportion of long chain unsaturated free fatty acids (FFA) enters the portal 
circulation [10].
According to the hypothesis on hepatic lipotoxic lesions, certain FFAs and their metabolites 
flow through the liver and cause NAFLD/NASH. Dietary intake plays an important role in 
the generation of FFA. Excess carbohydrate consumption, particularly fructose, leads to de 
novo lipogenesis. Excess calories and fats can result in accumulation of lipids in adipose tissue, 
and finally, the stored fatty acids are released through lipolysis. Free fatty acids generated 
by lipogenesis, lipolysis or other mechanisms have three potential destinations: triglycerides 
formation, oxidation and elimination, or intermediate lipid formation [11].
Hepatic mitochondria play an important role in the oxidation of fatty acids and in the syn-
thesis of ATP. Mitochondrial β-oxidation is a pathway for the elimination of fatty acids, 
but results in the generation of reactive oxygen species (ROS). In most circumstances, the 
endogenous antioxidant mechanisms are able to protect against cellular damage caused by 
ROS. However, in the configuration of impaired mitochondrial function related to obesity 
Figure 1. NAFLD mechanisms. Associated factors such as increased lipolysis and de novo hepatic lipogenesis (DNL), 
decreased free fatty acid oxidation and hepatic secretion of low density lipoprotein (VLDL) aggravate the onset of the 
disease. The action of Mitochondrial β-oxidation contributes to the synthesis of adenosine triphosphate (ATP), however 
results in the increase of reactive oxygen species.
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and chronic lipid overload, ROS lead to peroxidation of fatty acids, further interfering in 
mitochondrial function through oxidative damage to mitochondrial DNA and proteins [12].
The reason some obese individuals are able to regulate mitochondrial function and compen-
sate lipid overload, while others are not, are still unclear. Multiple pathways involving a com-
plex interaction between excess lipids, systemic inflammation and cellular stress probably 
contribute to the development and progression of NAFLD [13].
2.1. Crosstalk between obesity and NAFLD
Obesity is an important risk factor for non-alcoholic fatty liver disease (NAFLD). Although it is 
not a risk factor present in all obese individuals, a minority of patients with NAFLD are lean. 
In the survey conducted by the National Health and Nutrition Examination Survey III, 7.4% of 
lean adults and 27.8% of overweight/obese adults had hepatic steatosis that could be detected by 
ultrasound, which highlights the higher prevalence in overweight or obessed individuals. [14].
The pathophysiology of NAFLD is complex, since it is a multifactorial disease, whose disor-
ders contribute to the metabolic syndrome, involving obesity, diabetes mellitus, hypertension 
and dyslipidemia [15]. Patients with NAFLD and metabolic syndrome (MS) have a higher 
prevalence and severity of fibrosis and necroinflammatory activity, compared to individuals 
of NAFLD without MS. In addition, the presence of MS is associated with a high risk of NASH 
among NAFLD individuals, after correction for gender, age and body mass [15].
Insulin resistance, an important feature of MS and type 2 diabetes mellitus (DM 2), is clas-
sified as peripheral insulin resistance and/or hepatic insulin resistance [16, 17]. Peripheral 
insulin resistance refers primarily to decreased insulin-mediated glucose uptake in skeletal 
muscle and adipocytes, whereas hepatic insulin resistance relates to the inability of insulin 
to decrease hepatic glucose production. The accumulation of fat in skeletal muscle has been 
considered the main pathogenic event leading to resistance to peripheral insulin. Briefly, the 
accumulation of arachidonic acid fatty acid metabolites in the muscle initiates a series of sig-
naling reactions that increase the phosphorylation of specific serine residues (e.g, S307) on the 
insulin-1 receptor substrate (IRS-1) in the muscle. However, several researchers have begun 
to focus on the mechanism of hepatic insulin resistance [16, 17].
The IRS-1 is critical in its signaling, since it is an important target in the inflammatory process 
and, following serine phosphorylation of IRS-1, there is a reduction in the activation of phosphoti-
dylinositol-3-kinase (PI3k), as well as other proteins involved in the normal insulin signaling pro-
cess, such as protein kinase B (Akt). These deleterious events are shown to be mediated by proteins 
that activate inflammatory pathways, such as the c-Jun NH2-terminal kinase (JNK), the kinase IκB 
(Iκκβ) and PKCθ [18–21]. NFκB is a gene transcription factor that alters insulin signaling and after 
stimulation, Iκκβ is phosphorylated, lea̶ding to the translocation of NFκB to the cell nucleus and 
subsequent activation of proinflammatory cytokine genes, such as TNF-α, IL- 6 and IL-1β [22–24].
The mechanism of resistance to peripheral insulin point to the fat-induced induction of sev-
eral inflammatory signaling kinases (PKCθ, IKK-β and JNK1), which may in turn increase 
serine phosphorylation in IRS-1, thus preventing their participation in the insulin signaling 
cascade. As a result, the insulin capacity to increase GLUT4 translocation is impaired. The 
mechanisms of fat-induced hepatic insulin resistance are similar to peripheral resistance. 
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy90
Thus, accumulation of fat within the liver results in a blockage in insulin signaling in IRS-2. 
This proximal blockade in the insulin signaling cascade may limit the ability of insulin to 
activate hepatic glycogen synthesis and suppress hepatic glucose production, involving the 
role of PKC, IKK-β and/or JNK1 in the pathogenesis of hepatic insulin resistance induced by 
fat [17]. Based on a study of patients with diabetes, accumulation of fat in the liver may also 
be associated with increased hepatic gluconeogenesis [25].
In addition, the hormonal and biological activity of adipose tissue through the secretion of 
adipokines by white adipose tissue (WAT) contributes to the insulin and metabolic resistance 
of the disease, including NASH. This is due to the release of inflammatory cytokines by macro-
phages in the adipose tissue and the increased release of free fatty acids from adipocytes [12].
In the context of chronic overfeeding, white adipose tissue becomes expanded with lipids, lead-
ing to adipocyte hyperplasia or hypertrophy. The remodeling of white adipose tissue helps to 
accommodate adipocyte hypertrophy, but, eventually, impaired innervation and vascularization 
result in hypoxia and adipocyte dysfunction [26]. This dysfunction would increase adipocyte 
secretion mediated by JNK1 - inflammatory cytokines [27], resulting in increases and changes 
of immune cells in adipose tissue and eventual systemic metabolic stress with mitochondrial 
dysfunction, lipolysis, decreased lipid storage capacity and signaling rupture of insulin [28].
In addition, the Western dietary pattern with excessive intake of high-calorie, rich in fat, sugar 
and cholesterol and sedentary lifestyle are risk factors for hepatic steatosis. Such factors have an 
impact on lipid metabolism related to liver diseases, which include decreased conversion of cho-
lesterol to bile acids; increased hydrolysis of cholesterol esters to free cholesterol [29]; increased 
endogenous cholesterol synthesis [30]; increased absorption of cholesterol-rich lipoproteins [29]; 
and decreased cholesterol excretion [31]. Excess cholesterol influences the fluidity of the mem-
brane, affecting the function of its proteins [32]. It is also worth mentioning that this excessive 
consumption activates Kupffer cells and hepatic stellate cells, exacerbating liver inflammation, 
increasing extracellular matrix synthesis and eventually accelerating progress for NASH [33, 34].
3. Developing animal models of non-alcoholic hepatic steatosis
The progress of obesity with the presence of the NAFLD disorder is characterized as a very 
complex inflammatory process. Despite the search for new studies in the area, there are a 
number of challenges in conducting research with humans, especially to investigate genetic 
and dietary aspects. Controlling the diet and environment of humans becomes difficult for 
long periods of time, and ethical restrictions limit access to biological samples. Such problems 
can be circumvented with the use of animal models of disease [35].
Animal models are extremely important for elucidating the etiology of diseases in humans, 
besides having an integrated view of the pathogenic mechanisms, as well as monitoring the 
natural evolution of the disease under controlled genetic and environmental conditions. 
These models constitute important resources in the identification of targets and therapeutic 
agents that can prevent or revert diseases [36].
The choice of the animal model for studies of obesity is comprised mostly of small animals such 
as mice, rats, guinea pigs, hamsters, with the genetic, neuroendocrine and dietary alterations. 
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In these models, the disease can be induced through specific diets or with the use of chemical 
substances and may result in non-alcoholic hepatic steatosis [37–39].
Despite the diversity of existing models, it is of utmost importance that they can replicate 
the histological patterns and pathophysiological mechanisms characteristic of each stage of 
NAFLD in humans, develop comorbidities associated with this disease such as increase of 
body weight, peripheral resistance to insulin, dyslipidemia, release of adipokines by adipose 
tissue, among others [40].
Mice and rats are mammals belonging to the Muridae family and the Murinae subfamily, 
order Rodentia and genus of the mouse Mus, whose scientific name Mus musculus/domesticus 
and the rat of the genus Rattus and the species Rattus Norvegicus/rattus. Both are heavily used 
in research due to their practical handling and playback performance in short period of time. 
Its lineage classification may be as genetically variable (heterozygous) termed outbreed or 
genetically defined inbreed. Outbreds are non-consanguineous and heterogeneous, which 
brings them closer to representing natural populations, larger litters and lower mortality rate, 
for example the Swiss colony (NIH, Webster, ICR and CD-1) [41]. Conversely, inbreds are 
consanguineous and isogenic, from crossbreeding between siblings which determine them to 
be identical, such as C57BL/ J6, BALB/ C, C3H, FVB, 129, DBA and CBA [42, 43].
Controlled expression of some genes results in the animal model called transgenic, they 
are susceptible to genome changes with specific DNA fragments, may have a mutated or 
increased gene, and result in a genetic modification that is transmissible to their offspring. 
“Knockout” animals, i.e. animals having a knockout gene, have a total or partial sequence of 
a withdrawn gene, contributing to determine a pathology. And “knock-in” animals acquire 
a total or partial sequence of a gene introduced in their genome predisposing it to a certain 
pathology by excess of the gene product [44, 45].
Animals with genetic obesity or induced obesity (Table 1) present non-alcoholic hepatic steato-
sis, either by genetic alteration (Table 2) and increased lipid synthesis as in ob/ob mice, the db/db 
rat, agouti (obese yellow); and environmental factors such as diets deficient in methionine or 
choline, rich in carbohydrates or lipids and can also be combined with genetic alterations [46].
3.1. Genetic models
3.1.1. ob/ob mice
The ob/ob mice are spontaneous, obese mutants that do not have the Leptin gene (ob) which is 
autosomal recessive located on chromosome 6. From 4 weeks of age they are able to triple the 
normal weight when they are exposed to open offer of food due to lack of satiety caused by the 
absence of the hormone leptin. They are hypothermic and unable to stay warm. Its characteris-
tics go beyond obesity, including hyperphagia, diabetes and non-alcoholic hepatic steatosis that 
presents with 10–12 weeks of life. The ob/ob is considered a good model of obesity linked hepatic 
steatosis, since metabolism of lipids and carbohydrates is related to the amount of white adipose 
tissue (WAT), which is increased in obesity. WAT in abundance reflects on increased expression 
of TNF-alpha and lipolysis, whose fatty acids are released to the liver for deposition [47, 48]. In 
this model, for hepatic steatoectomy, regarded as a second stimulus or agent (“second hit” such as 
ischemia induction) specific drugs or methionine and choline-deficient diets, is needed [46, 49, 50].
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The ob/ob model behaves similarly to the methionine and choline deficiency models, since they 
affect oxidative stress, lipid peroxidation, and cell death. They are characterized by a chronic 
subclinical inflammatory condition with constant release of proinflammatory cytokines, 
monocyte infiltration of reactive oxygen species (ROS), oxidation of lipid molecules, choles-
terol and proteins present in low density lipoprotein (LDL). This is in addition to mitochon-
drial DNA damage (measured by the mitochondrial levels of 8-hydroxy-2′-deoxyguanosine) 
and reduced expression of the DNA mismatch repair enzyme [51, 52]. Lipid peroxidation of 
polyunsaturated fatty acids generates by-products of toxic aldehydes, including malondal-
dehyde and hydroxynonenal, which are more persistent than ROS and damage more distant 
intracellular organelles which can cause cell death. These products activate fibrous hepatic 
stellate cells and are chemotactic for neutrophils [53, 54].
Diet Concentration/nutrient Animal 
model
Follow-up Obesity NAFLD IR NASH
HFD SFAs 
+Cholesterol
15% +1%
30% +2%
49%
C57BL/J6
SD
C57BL/J6
30 weeks
48 weeks
3 months
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
HCD 30% fructose
70% fructose
65% sacarose
70% sacarose
30% fructose/glicose/sacarose
C57BL/J6
Wistar
C57BL/J6
Wistar
Sprague 
Dawley
4 months
5 weeks
8 weeks
4 weeks
4 months
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No
Yes
No
Yes
No
No
No
FF 40% HCD + 2% cholesterol e 
fructose drink
C57BL/J6 25 weeks Yes Yes Yes Yes
Table 1. Characteristics of obesity/NAFLD diet composition in various animal models.
Genetic 
models
Genetic alteration Characteristics Considerations “Second hit”: NASH
ob ob Absence of the leptin 
gene
Hyperphagia, Obesity, 
diabetes, IR and NAFLD
10–12 weeks is confirmed 
NAFLD.
Hepatotoxic stimuli, 
specifics diets
db db Deficient in leptin 
receptor
Obesity, IR, and NAFLD 3 months is confirmed 
NAFLD. Features similar 
to Nafld in humans.
Diet HFD or MCD
KK-AY knockout for 
melanocortin  
receptor 4
Obesity, hyperphagia, 
hyperinsulinemia, 
hyperglycaemia and NAFLD
Altered gene expression 
of lipid metabolism.
Diet MCD, a HFD or 
use of endotoxin
ACOX knockout mice for 
the enzyme acyl-
coenzyme A oxidase
Accumulation of fat at liver 1 week presented 
microvesicular steatosis. 
At 2 months, livers show 
extensive steatosis.
Not necessary
Table 2. Characteristics of mouse genetic models for the development of NAFLD.
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3.1.2. db/db mice and Zucker fa/fa rats and Koletsky f/f
Obese Zucker fa/fa rats and the db/db mouse are deficient in leptin receptor function, resulting 
from mutations in the leptin gene which occur on chromosome 4. Quite close phenotypically 
to these models is the obese Koletsky f/f rat which has the leptin deficiency with reduced 
energy expenditure and neuropeptidergic alterations of the hypothalamus [55].
Obese fa/fa Zucker rats fed with high fat diet (HFD) made with 60% of saturated lipids for 
8 weeks, confirmed the occurance of hyperglycemia and hepatic steatosis. NADPH oxidase 
activity increased 2.5-fold leading to hepatic liver injury of the animals thus contributing to 
the progression of NASH [56].
3.1.3. KK-ay mice and knockout for melanocortin receptor 4
The KK-Ay genotype results from the crossing of KK diabetic rats with yellow coat and agouti 
background (Ay) [57], they develop obesity due to the antagonistic action of the agouti pro-
tein in the central nervous system capable of promoting alimentary hyperphagia and con-
sequent obesity [58]. Changes in the genes of the agouti rat and in the encoding gene of the 
melanocortin receptor 4 (MC4R) are related to the involvement of the melanocortins system 
in the pathogenesis of NAFLD [59]. They present indicators of resistance to insulin and leptin, 
conditions that favor the appearance of hepatic steatosis. Also the genetic depletion of MC4R 
is associated with a severe obesity phenotype such as hyperphagia, hyperinsulinemia, hyper-
glycemia and hyperleptinemia [60]. To progress to NASH, a “second hit” is needed again as 
an example: diet MCD, a HFD or use of endotoxin [61].
3.1.4. ACOX and knockout mice for the enzyme acyl-coenzyme A oxidase
The enzyme acyl-coenzyme A oxidase-1 (ACOX 1) is the first enzyme of peroxisomal β-oxidation 
of long chain fatty acids. Peroxisomal and mitochondrial fatty acid beta-oxidation occuring in 
mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal 
fatty acyl-CoA oxidase (ACOX−/−) exhibits a wide range of microvesicular steatohepatitis. These 
animals develop NAFLD due to the accumulation of fat generated by impaired β-oxidation [62]. 
At 1 week of age, the liver of the AOX−/− mice already presented microvesicular steatosis, which 
intensifies at 2 months of age to inflammatory infiltration [63]. However, when they are 6 to 
8 months old, the liver of these mice exhibits reversal of steatosis from hepatocyte regeneration 
and also exhibits growth retardation [64].
3.2. Animal models induced by diets
3.2.1. High fat diet (HFD)
High fat diet (HFD) treated animals acquire obesity and also increased epididymal fat, hyper-
glycemia and insulin resistance, because these associated comorbidities are also widely used 
as a method of inducing hepatic steatosis, as they cause liver changes similar to that of human 
disease. Usually fat sources such as lard and soybean oil are used, different concentrations of 
lipids are taken into account in the preparation, varying in proportion from 40 to 60%. The 
most commonly used rodents are C57BL/6, Swiss, Sprague Dawley, Wistar and SHR [62, 65].
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A higher fat supply leads to increased adiposity in adipose tissue, frequent stimulation of pro-
inflammatory cytokines secretion, increased free fatty acids, insulin resistance, and lipolysis, 
with consequent increase in the transport of free fatty acids to the liver via the portal vein and 
increased intake of fatty acids. In the liver, hyperinsulinemia inhibits beta-oxidation, reduc-
ing the output of fatty acids, leading to unanticipated the accumulation of triglycerides in the 
cytoplasm of hepatocytes which hallmarks NAFLD. Both actions favor the accumulation of 
fat in the hepatocytes, a condition that promotes hepatic resistance to the action of insulin. 
Loss of insulin’s ability to suppress hepatic glucose production aggravates overall insulin 
resistance and exacerbates the manifestation of metabolic syndrome components [66–69].
The addition of cholesterol along with saturated fatty acids has shown to have a good disease 
predisposition, with progression of NAFLD to NASH. Savard et al. [70] tested the effect of this 
diet on the respective proportions of saturated fatty acids and cholesterol on the C57BL/J6 model 
for 30 weeks: control (4% fat and 0% cholesterol); high cholesterol[HC] (4% fat and 1% choles-
terol); high fat[HF] (15% fat and 0% cholesterol); and high fat, high cholesterol[HFHC] (15% fat 
and 1% cholesterol). The animals treated with HCHC showed the highest weight gain, hepatic 
lipid content, inflammation of adipose tissue and reduction in adiponectin plasma levels, lead-
ing to NAFLD in a profound way, as they developed macrovesicular steatosis (grade 3) associ-
ated with inflammatory spots (grade 2) and peripheral fibrosis, with these effects being twice as 
large as in the HC and HF groups [70].
Similarly, adult Sprague Dawley rats fed HFD made with 30% lipids (lard and 2% choles-
terol) were evaluated at 4, 8, 12, 16, 24, 36, 48 weeks intervals. At week 8 body weight and 
epididymal fat weight began to increase, which was associated with increased serum levels 
of free fatty acids, cholesterol and TNF-α, as well as the development of NAFLD fatty liver. 
Steatohepatitis occurred between weeks 12 and 48. Apparent hepatic fibrosis did not occur 
until week 24, and went from week 36 to 48 with insulin resistance reproducing the pathologi-
cal sequence of events typical of human NASH [71].
Obesity models induced by HFD consumption have also been characterized by inflammation 
in peripheral tissues as well as in hypothalamic areas critical for energy homeostasis, in an 
attempt to interrupt body weight control and glucose homeostasis [72]. According to Thaler 
et al. [73] unlike inflammation in peripheral tissues, which develops as a consequence of obe-
sity, inflammatory signaling of the hypothalamus is confirmed in rats and mice within 1 to 
3 days after initiation of HFD treatment, ie before substantial weight gain. In addition, both 
reactive glucose and markers suggestive of neuronal injury were evident in the arched hypo-
thalamic nuclei of rodents in the first week of dietary feeding, leading to the knowledge that 
obesity is associated with neuronal injury in an area of the brain, suggesting a crucial aspect 
for the control of body weight [73]. Induction of FHD obesity in AFasKO mice with death 
receptor Fas deficiency (also known as CD95), specifically in adipocyte cells, were protected 
from adipose tissue inflammation and also from hepatic steatosis (more sensitive to insulin, 
both at the level of the body and in the liver) and hepatic insulin resistance [74].
In C57BL/6 mouse fed with HF diet (49% of lipids) during gestation and/or lactation, or both, the 
presence of non-alcoholic fatty liver steatosis was verified by expression of protein-1c binding 
to the sterol regulatory element. There was an exacerbation of NAFLD phenotype in utero and 
during lactation, demonstrating the development of hepatic steatosis already in fetal life [75].
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3.2.2. High carbohydrate diet (HCD)
Prolonged consumption of HCD causes obesity and non-alcoholic fatty liver disease (NAFLD), 
in addition to oxidative stress in the liver and insulin resistance. The most common sources of 
simple carbohydrates in the diet are fructose, glucose and sucrose, for example the addition of 
corn syrup (50–90% fructose) or refined sugar (50% fructose). Fructose is highly lipogenic and 
has been more widely used than sucrose and glucose, however, induction of chronic models 
in NAFLD requires longer treatment periods [76–78]. Fructose is primarily metabolized in the 
liver without the need for insulin, its phosphorylation consumes ATP and accumulates ADP thus 
stimulating the formation of uric acid and reactive oxygen species (ROS) which rapidly increases 
the synthesis and hepatic deposition of triglycerides leading to a fatty liver in rodents [79–81].
Treatment with a 30% fructose, glucose and sucrose diet for 4 months in Sprague Dawley rats 
demonstrated that such treatment induced metabolic syndrome, intrahepatic accumulation of 
uric acid and triglycerides, increased MCP-1 and TNF-alpha, as well as hepatic steatosis [82]. 
This simple carbohydrate intake is associated with a greater translocation of the endotoxin 
from the intestine to the portal vein, ROS formation in the liver (due to the greater oxidation 
of fatty acids in the hepatocytes) and induction of the TNF-alpha factor. TNF-alpha has been 
associated with the development of NAFLD because it is involved in the dysregulation of 
hepatic lipid metabolism and in insulin signaling [83, 84].
The C57BL/6 mouse model fed a high calorie and sucrose diet (65%) for 8 weeks showed obe-
sity, insulin resistance and macrovesicular steatosis [85]. In another study with C57BL/J6 mice 
with TNF-alpha receptor 1/− TNFR1/− (sterol regulatory element-binding protein 1) were pro-
tected against the onset of hepatic steatosis and also the insulin resistance induced by HCD 
with fructose (30%), this result was associated with increased phosphate levels of adenos-
ine monophosphate-activated protein kinase (AMPK) and protein kinase (AKT), decreased 
expression of SREBP-1, fatty acid synthesis in the liver and decreased levels of retinol binding 
protein (RBP4) that behaved differently from the control group [86].
As with Wistar rats, the effect of the sucrose diet (70%) when compared to starch (70%) for 28 days 
resulted in a significant difference in the group that received sucrose, thus the amount of hepatic 
fat and serum fructosamine concentration was increased in sucrose diet group and in both hepatic 
steatosis confirmed in the two groups [87]. However, when using HCD with 70% fructose for 
5 weeks, obesity, elevated levels of hepatic triglycerides, macrovesicular steatosis, lobular inflam-
mation (as were observed [88]. Another report with the same animal model in (HCD) added 10% 
of fructose (corn syrup) in drinking water and evaluated at 7, 14 and 21 days. At the start of 
treatment, an increase in triglycerides,oxidative stress and hepatic sensitivity to hyperinsulinemia 
(β-cell reaction) were was observed in serum and liver, suggesting that this increase is related to 
metabolism that occurred in the liver and probably in the adipose tissue as well [89].
Epidemiological studies have shown that increasing the intake of fructose mono- or disac-
charides by humans is a considerable risk factor for NALFD [90, 91], and it is estimated that 
patients with fructosemia present a fructose consumption about 2–3 times higher than healthy 
individuals or with other liver diseases [92]. These data stimulated the study of experimental 
models of NAFLD induced by fructose.
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3.2.3. Fast food diet (FF)
Charlton et al. [93] proposed the mouse fast food diet model. C57BL/6 mice were fed for 
25 weeks on a diet composed of 40% fat (12% saturated fatty acids, 2% cholesterol) and the 
water offered contained corn syrup, it was found that the animals developed obesity and 
resistance to insulin. I Other studies used the same model and also stated that the intake of FF 
diet in the form of emulsion for 6 weeks led to the onset of hepatic steatosis and inflammation, 
and elevated levels of endotoxemia and glycemia [86].
This diet model was very similar to the Western diet, since it presents high concentrations of 
fat, fructose and cholesterol, appearing as a good model related to human diets and with the 
capacity to induce obesity, NAFLD among other comorbidities in rodents.
3.3. Combined models (genetic and environmental)
The use of the C57BL LDLr male mouse (low density lipoprotein receptor deficient) treated 
for 21 weeks with HFD, was associated with weight gain, macrovesicular steatosis and lobular 
inflammation. Inflammation in adipose tissue and liver provides a positive attenuation for stud-
ies of obesity and associated cardiometabolic diseases such as NAFLD and atherosclerosis [94].
db/db mice subjected to methionine and choline deficient diet (MCD) showed macrovesicular 
steatosis, and increased hepatic collagen type 1 mRNA levels in comparison to the control 
group. This outcome suggests an important model for the study of NASH, i.e. establishing 
obesity, diabetes, insulin resistance and dietary MCD results in steatohepatitis indicating 
leptin activity in liver fibrosis. In this way, an interesting comparison is made with the ob/ob 
model that is deficient in leptin which also develops steatohepatitis but not hepatic fibrosis 
when fed with the MCD diet [95].
The verification in the obese and diabetic C57BI/6-A and KK-Ay models of diet treatment 
(MCD) for 8 weeks demonstrated that KK-Ay rats exhibited increased susceptibility to ste-
atohepatitis and inflammatory infiltration as well as increased levels of TNFα mRNA and 
lipid peroxidation in the liver where hypoadiponectinemia probably played a key role in the 
exacerbation of inflammatory and profibrogenic responses [96].
The treatment of the KK-Ay (MC4R) model with hyperlipidic diets at concentrations of 35 and 
60% of lipids derived from soybean oil and lard, develop severe hepatic steatosis and show 
liver changes in the lipogenic gene profile [97]. Another study has shown that the exposure of 
these animals to 60% HFD for 1 year leads to the appearance of more severe forms of NAFLD 
such as NASH, fibrosis and hepatocellular cancer, as well as leading to the development of 
systemic metabolic alterations very similar to those observed in humans [98]. This same model 
was used for a study of hepatic lesions induced by D-galactosamine/lipopolysaccharide LPS 
(GalN/LPS) endotoxin, there were significant increases in the levels of aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) in the blood, apoptotic and necrotic changes 
in hepatocytes and/or showed a high degree of lethality. GalN/LPS-induced liver injury was 
more pronounced in KK-Ay obese than in the control group [61]. LPS is a key component of 
many bacteria present in the microbiota, plays a central role in innate immune responses and 
is considered the second hit in NASH models [99].
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4. Conclusion
It is very clear that mechanisms responsible for the development of NAFLD, which can occur 
through a diet, typically western diet, rich in saturated fat and fructose, in addition to other 
simple sugars, promotes metabolic disorders. This initially affects processes such as liver lipo-
genesis, resistance to insulin, and even as it is now known, negative consequences due to an 
unbalanced microbiota, with greater release of LPS. Studies on the mechanisms involved in the 
development of NAFLD and progression to NASH has steadily increased, due to the increas-
ing number of obesity and liver disorders worldwide. The combination of factors that interfere 
with etiology such as weight gain, dietary ingredients and genetics are factors that further insti-
gate the urgency to elucidate its effects on the liver using animal models of human diseases.
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